Wnt and GSK3 Signaling Pathways in Bipolar Disorder: Clinical and Therapeutic Implications
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The neurobiology of bipolar disorder, a chronic and systemic ailment is not completely understood. The bipolar phenotype manifests in myriad ways, and psychopharmacological agents like lithium have long term beneficial effects. The enzyme glycogen synthase kinase 3 (GSK3) has come into focus, as lithium and several other mood stabilizing medications inhibit its activity. This kinase and its key upstream modulator, Wnt are dysregulated in mood disorders and there is a growing impetus to delineate the chief substrates involved in the development of these illnesses. In May 2016, a comprehensive literature search was undertaken which revealed that there is over activity of GSK3 in bipolar disorder with deleterious downstream effects like proinflammatory status, increased oxidative stress, and circadian dysregulation leading to declining neurotrophic support and enhanced apoptosis of neural elements. By developing specific GSK3 inhibitors the progressive worsening in bipolar disorder can be forestalled with improved prospects for the sufferers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Polter, A., Beurel, E., Yang, S., Garner, R., Song, L., Miller, C. A., Sweatt, J. D., McMahon, L., Bartolucci, A. A., Li, X., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.43 · Cited by 225
Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers
Muneer, A. (2016) · Psychiatry Investigation · doi:10.4306/pi.2016.13.1.18 · Cited by 187
Self-citation
Cited by
The Case for TAAR1 as a Modulator of Central Nervous System Function
Rutigliano, G., Accorroni, A., & Zucchi, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00987 · Cited by 166
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
GSK3β: a master player in depressive disorder pathogenesis and treatment responsiveness
Duda, P., Hajka, D., Wójcicka, O., Rakus, D., & Gizak, A. (2020) · Cells · doi:10.3390/cells9030727 · Cited by 84
Yang, X.-H., Song, S.-Q., & Xu, Y. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150028 · Cited by 84
“…with the fact that the canonical Wnt signaling pathway has been reported to be implicated in mood disorders such as bipolar disorder and major depression, 25,26 the protein expression levels of BDNF and the Wnt/ β -catenin pathway were further investigated in CUMS rats in the present study.”
BackgroundSerafini, G., Pardini, M., Monacelli, F., Orso, B., Girtler, N., Brugnolo, A., Amore, M., Nobili, F., & Team on Dementia of the IRCCS Ospedale Policlinico San Martino (2021) · Brain Sciences · doi:10.3390/brainsci11020276 · Cited by 56
“Furthermore, ccording to Muneer [76], the enzyme glycogen synthase kinase 3 (GSK3) and its key up tream modulator, W t, have b en proposed to be dysregulated in BD.”
Background
Metadata
- Authors
- Muneer, A.
- Venue
- Clinical Psychopharmacology and Neuroscience
- Published
- 2017-05-31
- Volume
- 15
- Issue
- 2
- Pages
- 100-114
- ISSN
- 1738-1088 (ISSN-L)
- 2093-4327
- OpenAlex
- W2608855643
- Cited by
- 94
- References
- 3
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.